In Situ Peptide Self‐Assembly Augments Antibody Recruitment for Tumor Immunotherapy
Abstract
ABSTRACT In innate immune regulation‐based therapy, the degree of killing by innate immunity depends on the number of antibodies binding on the tumor cells. It is well known that antibodies can only bind to tumor cells by interacting with specific receptors. However, there is little receptor expression on the surface of tumor cells, so it becomes a challenge to recruit a sufficiently large number of antibodies to activate innate immunity. Here, we developed a peptide self‐assembly antibody recruitment strategy (SARS), which uses intermolecular non‐covalent forces of assembled peptides, resulting in a large number of peptide molecules on the tumor surface. The assembly exhibits a fivefold increase in antibody recruitment capacity compared to the monomer, resulting in a fivefold enhancement of the final immune‐mediated killing effect. This strategy reduces the dependence on cell surface antigens, demonstrating that self‐assembled antibody‐recruiting molecules have strong antibody‐recruiting as well as tumor cell‐killing abilities in vitro and in vivo. These findings emphasize the potential of self‐assembled peptides as a promising novel antibody‐recruiting nanomaterial for cancer immunotherapy.
Article Details
Authors (8)
Yu Wang
Xiu‐Hai Wu
Department of Urology Harbin Medical University Cancer Hospital NHC Key Laboratory of Molecular Probe and Targeted Theranostics Harbin Medical University Harbin Heilongjiang Province China
Zi‐Mo Liu
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology (NCNST) Beijing P. R. China
Si‐Kai Cao
Department of Urology Harbin Medical University Cancer Hospital NHC Key Laboratory of Molecular Probe and Targeted Theranostics Harbin Medical University Harbin Heilongjiang Province China
Xiao‐Wei Xie
Department of Urology Harbin Medical University Cancer Hospital NHC Key Laboratory of Molecular Probe and Targeted Theranostics Harbin Medical University Harbin Heilongjiang Province China
Zi‐Qi Wang
Department of Urology Harbin Medical University Cancer Hospital NHC Key Laboratory of Molecular Probe and Targeted Theranostics Harbin Medical University Harbin Heilongjiang Province China
Zeng‐Ying Qiao
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety National Center for Nanoscience and Technology (NCNST) Beijing P. R. China
Hao Wang
Division of Quantitative Sciences, Department of Oncology Johns Hopkins University School of Medicine Baltimore Maryland USA